Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Agios Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2026 was MXN1,739 Mil.
Agios Pharmaceuticals's quarterly Ending Cash Position
increased
from Dec. 2025 (MXN1,605 Mil) to Mar. 2026 (MXN2,049 Mil) but then
declined
from Mar. 2026 (MXN2,049 Mil) to Jun. 2026 (MXN1,739 Mil).
Agios Pharmaceuticals's annual Ending Cash Position
increased
from Dec. 2023 (MXN1,497 Mil) to Dec. 2024 (MXN1,590 Mil) and
increased
from Dec. 2024 (MXN1,590 Mil) to Dec. 2025 (MXN1,605 Mil).
Agios Pharmaceuticals Ending Cash Position Related Terms
Agios Pharmaceuticals Ending Cash Position Historical Data
* Premium members only.
The historical data trend for Agios Pharmaceuticals's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agios Pharmaceuticals Ending Cash Position Calculation
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
Agios Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of MXN1,739 Mil mean?
Agios Pharmaceuticals (MEX:AGIO) has a Ending Cash Position of MXN1,739 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Agios Pharmaceuticals and its competitors.
Is Agios Pharmaceuticals' Ending Cash Position too high?
Agios Pharmaceuticals' current Ending Cash Position is MXN1,739 Mil. Overall, Agios Pharmaceuticals has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Ending Cash Position compare to BHVN and VRDN?
Agios Pharmaceuticals' Ending Cash Position of MXN1,739 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current Ending Cash Position is MXN1,739 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Agios Pharmaceuticals (MEX:AGIO) has a current Ending Cash Position of MXN1,739 Mil. The stock's GF Value™ is MXN4,018.52, compared to a current price of MXN1,222.00 — trading 69.6% below its estimated fair value. The current Ending Cash Position is MXN1,739 Mil. Agios Pharmaceuticals' overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Agios Pharmaceuticals (MEX:AGIO), the current Ending Cash Position is MXN1,739 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agios Pharmaceuticals (MEX:AGIO) Overvalued in 2026?
Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN1,222.00 is trading 69.6% below its estimated GF Value™ of MXN4,018.52.
Key valuation signals for MEX:AGIO:
Ending Cash Position: MXN1,739 Mil
GF Value™: MXN4,018.52 vs. price of MXN1,222.00 (69.6% below fair value)
No single metric tells the full story. See the MEX:AGIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
47GF Score
Get the complete analysis for MEX:AGIO
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AGIO has been successfully added to your 
